Swedish Orphan Biovitrum AB (Sobi) announced that it has completed the acquisition from AstraZeneca of rights to Synagis (palivizumab) in the US as well as rights to participate in 50% of the future earnings of the
Swedish Orphan Biovitrum AB (Sobi) announced that it has completed the acquisition from AstraZeneca of rights to Synagis (palivizumab) in the US as well as rights to participate in 50% of the future earnings of the
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
![Zonder mens geen merk: waarom AI nooit merkvertrouwen kan automatiseren [onderzoek]](https://www.pharmamarketeer.nl/wp-content/uploads/2025/11/206-80x60.jpg)